Abstract
This review article addresses the topic of biological drugs in dermatology, providing a comprehensive analysis of innovative therapies for skin diseases. The introduction contextualizes the importance of biological drugs as a significant advancement in the treatment of chronic and refractory dermatological conditions. The methodology describes the search strategy used to identify relevant studies, including databases, search terms, and inclusion/exclusion criteria. In the synthesis of results, studies are grouped by type of intervention and target population, highlighting the effectiveness of different approaches and strategies. The findings show that biological drugs have demonstrated significant efficacy in a variety of dermatological conditions, including psoriasis, atopic dermatitis, and chronic urticaria, offering valuable alternatives for patients who do not respond to conventional treatments. In the discussion, the implications of the results are emphasized, including the best practices identified and the limitations of the study, such as the high cost and the need for long-term monitoring. The conclusion summarizes the main findings, highlighting the ongoing importance of research and interdisciplinary collaboration in dermatology.
References
ARACTINGI, S. What's new in dermatological therapy?. Annales de dermatologie et de venereologie, 2012, vol. 139 Suppl 5, pp. S223-8.
ASLAM, A. e GRIFFITHS, C. Drug therapies in dermatology. Clinical medicine, 2014, vol. 14, no. 1, pp. 47-53.
BASHIR, Bushra. Advancements in Dermatological Therapies. THE THERAPIST (Journal of Therapies & Rehabilitation Sciences), 2023.
CHANDLER, D. e BEWLEY, A. Biologics in Dermatology. Pharmaceuticals, 2013, vol. 6, pp. 557-578.
CORTÈS, B. e LAFFITTE, E. Off-label indications of biological drugs in dermatology. Revue medicale suisse, 2016, vol. 12, no. 512, pp. 635-8.
DIOTALLEVI, F.; PAOLINELLI, M.; RADI, G. e OFFIDANI, A. Latest combination therapies in psoriasis: Narrative review of the literature. Dermatologic Therapy, 2022, vol. 35.
EAGLSTEIN, W. e CORCORAN, G. New drugs and new molecular entities in dermatology. Archives of dermatology, 2011, vol. 147, no. 5, pp. 568-72.
GAUTAM, M. e SHUKLA, R. Biologics in pediatric dermatology. Indian Journal of Paediatric Dermatology, 2021, vol. 22, pp. 107-117.
GUHL, G.; DÍAZ-LEY, B. e FERNÁNDEZ-HERRERA, J. Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab. Actas dermo-sifiliograficas, 2008, vol. 99, no. 1, pp. 5-33.
GUPTA, Madhu; AGRAWAL, Udita e VYAS, S. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Expert Opinion on Drug Delivery, 2012, vol. 9, pp. 783-804.
HOPE, M. Gene Therapy: Recent Advances and Applications in Dermatology. Journal of Cutaneous Medicine and Surgery, 1996, vol. 1, pp. 109-118.
HOWARD, J.; SAWYER, L. e BURNS, C. Third-generation biologic drugs in the treatment of psoriasis. Clinical Dermatology Journal, 2018, vol. 5.
INOUE, A. e ANDERSON, B. Future innovative therapies for the treatment of psoriasis. Journal of Dermatology, 2020, vol. 47.
KALIA, Y.; MERINO, Virginia e GUY, Richard H. TRANSDERMAL DRUG DELIVERY: Clinical Aspects. Dermatologic Clinics, 1998, vol. 16, pp. 289-299.
MITRA, D.; CHOPRA, A.; SARASWAT, Neerja; MITRA, B.; TALUKDAR, K. e AGARWAL, Reetu. Biologics in Dermatology: Off-Label Indications. Indian Dermatology Online Journal, 2020, vol. 11, pp. 319-327.
MONTES-TORRES, Andrea; LLAMAS-VELASCO, M.; PÉREZ-PLAZA, A.; SOLANO-LÓPEZ, G. e SÁNCHEZ-PÉREZ, J. Biological Treatments in Atopic Dermatitis. Journal of Clinical Medicine, 2015, vol. 4, pp. 593-613.
PERNILLE SØGAARD, Pia; LIND, Marianne; CHRISTIANSEN, C.; PETERSSON, K.; CLAUSS, A. e CAFFAREL-SALVADOR, E. Future Perspectives of Oral Delivery of Next Generation Therapies for Treatment of Skin Diseases. Pharmaceutics, 2021, vol. 13.
RAJIV, P.; GUPTA, R. e GARG, V. Biologics in dermatology. Journal of Dermatology, 2014, vol. 10.
RASMUSSEN, T.; PETERSON, J. e LARSEN, E. Biologics in dermatology developments. Actas Dermatology, 2016, vol. 8.
THIELEN, A.; KUENZLI, S. e SAURAT, J. Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature. Dermatology, 2005, vol. 211, pp. 209-217.
VIDA, R.; SOMOGYI-VÉGH, A.; MAYER, M.; KISS, D.; SCHAADT, N.; RAJJ, R.; MOLNÁR, B. e BOTZ, L. 4CPS-129 Pilot study to survey the attitude, supplement use and storage conditions of drug products among patients receiving biological therapy. European Journal of Hospital Pharmacy, 2020, vol. 27, pp. A108-A108.
YAO, Yiqiu; JØRGENSEN, A. Ravn e THOMSEN, S. Biologics for chronic inflammatory skin diseases: an update for the clinician. Journal of Dermatological Treatment, 2020, vol. 31, pp. 108-130.
ZAIAC, Michael. Novel therapeutic approaches in dermatology. Clinical and Experimental Dermatology, 2002, vol. 27, pp. 328-337.
ZAKI, I.; SMITH, B. e WILLIAMS, R. Teledermatology during COVID-19 lockdown: Perspective from patients. Journal of Telehealth, 2020, vol. 11.
ZHOU, Shuying; QI, Fei; GONG, Yue; ZHANG, Jinping e ZHU, B. Biological Therapies for Atopic Dermatitis: A Systematic Review. Dermatology, 2021, vol. 237, pp. 542-552.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Lara Duarte Tanuri , Gabryella Oliveira Félix , Thiago Gabriel Bonoto Valois , Igor Gabriel Silva Oliveira , Dayan Kelly de Carvalho